Sarah M. McGlone

The economic burden of Clostridium difficile

Although Clostridium difficile (C. difficile) is the leading cause of infectious diarrhoea in hospitalized patients, the economic burden of this major nosocomial pathogen for hospitals, third-party payers and society remains unclear. We developed an economic computer simulation model to determine the costs attributable to healthcare-acquired C. difficile infection (CDI) from the hospital, third-party payer and societal perspectives. Sensitivity analyses explored the effects of varying the cost of hospitalization, C. difficile-attributable length of stay, and the probability of initial and secondary recurrences. The median cost of a case ranged from

Would school closure for the 2009 H1N1 influenza epidemic have been worth the cost?: a computational simulation of Pennsylvania

9179 to

Social Network Analysis of Patient Sharing Among Hospitals in Orange County, California

11 456 from the hospital perspective,

Modeling the Spread of Methicillin-Resistant Staphylococcus aureus (MRSA) Outbreaks throughout the Hospitals in Orange County, California

8932 to

The Benefits To All Of Ensuring Equal And Timely Access To Influenza Vaccines In Poor Communities

11 679 from the third-party payor perspective, and

Economic value of norovirus outbreak control measures in healthcare settings.

13 310 to

To Test or to Treat? An Analysis of Influenza Testing and Antiviral Treatment Strategies Using Economic Computer Modeling

16 464 from the societal perspective. Most of the costs incurred were accrued during a patients primary CDI episode. Hospitals with an incidence of 4.1 CDI cases per 100 000 discharges would incur costs ≥

Economic Impact of Outbreaks of Norovirus Infection in Hospitals

3.2 million (hospital perspective); an incidence of 10.5 would lead to costs ≥

Pricing of new vaccines.

30.6 million. Our model suggests that the annual US economic burden of CDI would be ≥

The economic value of screening haemodialysis patients for methicillin-resistant Staphylococcus aureus in the USA.

496 million (hospital perspective), ≥